Saudatu Chinade Ja’aFaru

Saudatu Chinade Ja’aFaru

Auto-generated profile, based on publicly available information

Saudatu Chinade Ja’aFaru

Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSaudatu Chinade Ja’aFaru
Saudatu Chinade Ja’aFaru
AUAdamu Uzairu
Adamu Uzairu
IBimren Bayıl
imren Bayıl
MSMuhammed Sani Sallau
Muhammed Sani Sallau
GNGeorge Iloegbulam Ndukwe
George Iloegbulam Ndukwe
NANurul Absar
Nurul Absar
Schistosomiasis is a neglected tropical disease which imposes a considerable and enduring impact on affected regions, leading to persistent morbidity, hindering child development, diminishing productivity, and imposing economic burdens. Due to the emergence of drug resistance and limited management options, there is need to develop additional effective inhibitors for schistosomiasis. In view of this, quantitative structure-activity relationship studies, molecular docking, molecular dynamics simulations, drug-likeness and pharmacokinetics predictions were applied to 39 Schistosoma mansoni Thioredoxin Glutathione Reductase (SmTGR) inhibitors. The chosen QSAR model demonstrated robust statistical parameters, including an R2 of 0.798, R2adj of 0.767, Q2cv of 0.681, LOF of 0.930, R2test of 0.776, and cR2p of 0.746, confirming its reliability. The most active derivative (compound 40) was identified as a lead candidate for the development of new potential non-covalent inhibitors through ligand-based design. Subsequently, 12 novel compounds (40a-40l) were designed with enhanced anti-schistosomiasis activity and binding affinity. Molecular docking studies revealed strong and stable interactions, including hydrogen bonding, between the designed compounds and the target receptor. Molecular dynamics simulations over 100 nanoseconds and MM-PBSA free binding energy (ΔGbind) calculations validated the stability of the two best-designed molecules. Furthermore, drug-likeness and pharmacokinetics prediction analyses affirmed the potential of these designed compounds, suggesting their promise as innovative agents for the treatment of schistosomiasis.

26 September 2023 in Chemistry Africa
Verified
Journal Article
Closed access
PDF file
SJSaudatu Chinade Ja’aFaru
Saudatu Chinade Ja’aFaru
AUAdamu Uzairu
Adamu Uzairu
MSMuhammed Sani Sallau
Muhammed Sani Sallau
GNGeorge Iloegbulam Ndukwe
George Iloegbulam Ndukwe
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim
ADAmmar Usman Danazumi
Ammar Usman Danazumi

12 September 2024 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SJSaudatu Chinade Ja'Afaru
Saudatu Chinade Ja'Afaru
AUAdamu Uzairu
Adamu Uzairu
SHSharika Hossain
Sharika Hossain
MUMohammad Hamid Ullah
Mohammad Hamid Ullah
MSMuhammed Sani Sallau
Muhammed Sani Sallau
AMAbu Tayab Moin
Abu Tayab Moin
Schistosomiasis, also known as bilharzia or snail fever, is a tropical parasitic disease resulting from flatworms of the Schistosoma genus. This often overlooked disease has significant impacts in affected regions, causing enduring morbidity, hindering child development, reducing productivity, and creating economic burdens. Praziquantel (PZQ) is currently the only treatment option for schistosomiasis. Given the potential rise of drug resistance and the limited treatment choices available, there is a need to develop more effective inhibitors for this neglected tropical disease (NTD). In view of this, quantitative structure-activity relationship studies (QSAR), molecular docking, molecular dynamics simulations, drug-likeness, and ADMET predictions were applied to 31 inhibitors of Schistosoma mansoni Dihydroorotate dehydrogenase (SmDHODH). The designed QSAR model demonstrated robust statistical parameters including an R2 of 0.911, R2adj of 0.890, Q2cv of 0.686, R2pred of 0.807, and cR2p of 0.825, confirming its robustness. Compound 26, identified as the most active derivative, emerged as a lead candidate for new potential inhibitors through ligand-based drug design. Subsequently, 12 novel compounds (26A-26L) were designed with enhanced inhibition activity and binding affinity. Molecular docking studies revealed strong and stable interactions, including hydrogen bonding and hydrophobic interactions, between the designed compounds and the target receptor. Molecular dynamics simulations over 100 nanoseconds and MM-PBSA free binding energy (ΔGbind) calculations validated the stability of the two best-designed molecules (26A and 26L). Furthermore, drug-likeness and ADMET prediction analyses affirmed the potential of these designed compounds, suggesting their promise as innovative agents for treating schistosomiasis.

27 November 2024 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
SJSaudatu Chinade Ja'AFaru
Saudatu Chinade Ja'AFaru
AUAdamu Uzairu
Adamu Uzairu
VMVipin Kumar Mishra
Vipin Kumar Mishra
MSMuhammed Sani Sallau
Muhammed Sani Sallau
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim
ADAmit Dubey
Amit Dubey

26 February 2024 in Journal of Taibah University Medical Sciences
Verified
Journal Article
Open access
SJSaudatu C. Ja'AFaru
Saudatu C. Ja'AFaru
AUAdamu Uzairu
Adamu Uzairu
ACAnshuman Chandra
Anshuman Chandra
MSMuhammed S. Sallau
Muhammed S. Sallau
GNGeorge I. Ndukwe
George I. Ndukwe
IQImteyaz Qamar
Imteyaz Qamar
Schistosomiasis, a neglected tropical disease, is a leading cause of mortality in affected geographic areas. Currently, because no vaccine for schistosomiasis is available, control measures rely on widespread administration of the drug praziquantel (PZQ). The mass administration of PZQ has prompted concerns regarding the emergence of drug resistance. Therefore, new therapeutic targets and potential compounds are necessary to combat schistosomiasis. Twenty-four potent derivatives of PZQ were optimized via density functional theory (DFT) at the B3LYP/6-31G∗ level. Quantitative structureactivity relationship (QSAR) models were generated and statistically validated, and a lead candidate was selected to develop therapeutic options with improved efficacy against schistosomiasis. The biological and binding energies of the designed compounds were evaluated. In addition, molecular dynamics; drug-likeness; absorption, distribution, metabolism, excretion, and toxicity (ADMET); and DFT studies were performed on the newly designed compounds. Five QSAR models were generated, among which model 1 had favorable validation parameters (R2train: 0.957, R2adj: 0.941, LOF: 0.101, Q2cv: 0.906, and R2test: 0.783) and was chosen to identify a lead candidate. Other statistical parameters for the chosen model included variance inflation factor values ranging from 1.242 to 1.678, and a Y-scrambling coefficient (cRp2) of 0.747. Five new compounds were designed with improved predicted activity (ranging from 5.081 to 7.022) surpassing those of both the lead compound and PZQ (predicted pEC50 of 5.545). Molecular dynamics simulation revealed high binding affinity of the proposed compounds toward the target receptor. ADMET and drug-likeness assessments indicated adherence to Lipinski's rule of five criteria, thereby suggesting pharmacological and oral safety. In addition, DFT analysis indicated resistance to electronic alteration during chemical reactions. The proposed compounds exhibited potential drug characteristics, thus indicating their suitability for further investigation to enhance schistosomiasis treatment options.

5 September 2024 in Molecular Simulation
Verified
Journal Article
Closed access
SJSaudatu Chinade Ja’afaru
Saudatu Chinade Ja’afaru
AUAdamu Uzairu
Adamu Uzairu
VMVipin Kumar Mishra
Vipin Kumar Mishra
MSMuhammed Sani Sallau
Muhammed Sani Sallau
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim
ADAmit Dubey
Amit Dubey